What Does Rachel Sherman Think About Top FDA Regulatory Issues?

14 Feb 2018

Speaking at the BIO CEO & Investor Conference, US agency's No. 2 official talks about compassionate use, opioids, clinical trial design, and the agency's succession plan.

Greenwood adn Sherman — BIO CEO James Greenwood and FDA's Rachel Sherman at BIO CEO & Investor Conference • Source: Photo by Brenda Sandburg

What Does Rachel Sherman Think About Top FDA Regulatory Issues?

More from US FDA

More from Agency Leadership